Literature DB >> 29722902

Tolerance to high-internalizing δ opioid receptor agonist is critically mediated by arrestin 2.

Ana Vicente-Sanchez1, Isaac J Dripps1,2, Alycia F Tipton1, Heba Akbari1, Areeb Akbari1, Emily M Jutkiewicz2, Amynah A Pradhan1.   

Abstract

BACKGROUND AND
PURPOSE: Opioid δ receptor agonists are potent antihyperalgesics in chronic pain models, but tolerance develops after prolonged use. Previous evidence indicates that distinct forms of tolerance occur depending on the internalization properties of δ receptor agonists. As arrestins are important in receptor internalization, we investigated the role of arrestin 2 (β-arrestin 1) in mediating the development of tolerance induced by high- and low-internalizing δ receptor agonists. EXPERIMENTAL APPROACH: We evaluated the effect of two δ receptor agonists with similar analgesic potencies, but either high-(SNC80) or low-(ARM390) internalization properties in wild-type (WT) and arrestin 2 knockout (KO) mice. We compared tolerance to the antihyperalgesic effects of these compounds in a model of inflammatory pain. We also examined tolerance to the convulsant effect of SNC80. Furthermore, effect of chronic treatment with SNC80 on δ agonist-stimulated [35 S]-GTPγS binding was determined in WT and KO mice. KEY
RESULTS: Arrestin 2 KO resulted in increased drug potency, duration of action and decreased acute tolerance to the antihyperalgesic effects of SNC80. In contrast, ARM390 produced similar effects in both WT and KO animals. Following chronic treatment, we found a marked decrease in the extent of tolerance to SNC80-induced antihyperalgesia and convulsions in arrestin 2 KO mice. Accordingly, δ receptors remained functionally coupled to G proteins in arrestin 2 KO mice chronically treated with SNC80. CONCLUSIONS AND IMPLICATIONS: Overall, these results suggest that δ receptor agonists interact with arrestins in a ligand-specific manner, and tolerance to high- but not low-internalizing agonists are preferentially regulated by arrestin 2.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29722902      PMCID: PMC6016618          DOI: 10.1111/bph.14353

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Direct and differential interaction of beta-arrestins with the intracellular domains of different opioid receptors.

Authors:  B Cen; Y Xiong; L Ma; G Pei
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists.

Authors:  Iness Charfi; Karim Nagi; Ouissame Mnie-Filali; Dominic Thibault; Gianfranco Balboni; Peter W Schiller; Louis-Eric Trudeau; Graciela Pineyro
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

4.  Experimental design and analysis and their reporting: new guidance for publication in BJP.

Authors:  Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

5.  Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance.

Authors:  Amynah A A Pradhan; Wendy Walwyn; Chihiro Nozaki; Dominique Filliol; Eric Erbs; Audrey Matifas; Christopher Evans; Brigitte L Kieffer
Journal:  J Neurosci       Date:  2010-12-08       Impact factor: 6.167

6.  Type-specific sorting of G protein-coupled receptors after endocytosis.

Authors:  P I Tsao; M von Zastrow
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

7.  Differential association of receptor-Gβγ complexes with β-arrestin2 determines recycling bias and potential for tolerance of δ opioid receptor agonists.

Authors:  Nicolas Audet; Iness Charfi; Ouissame Mnie-Filali; Mohammad Amraei; Anne-Julie Chabot-Doré; Magali Millecamps; Laura S Stone; Graciela Pineyro
Journal:  J Neurosci       Date:  2012-04-04       Impact factor: 6.167

Review 8.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

Review 9.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.

Authors:  Eric Reiter; Seungkirl Ahn; Arun K Shukla; Robert J Lefkowitz
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-19       Impact factor: 13.820

10.  Neuroimmune Regulation of GABAergic Neurons Within the Ventral Tegmental Area During Withdrawal from Chronic Morphine.

Authors:  Anna M W Taylor; Annie Castonguay; Atefeh Ghogha; Pia Vayssiere; Amynah A A Pradhan; Lihua Xue; Sadaf Mehrabani; Juli Wu; Pat Levitt; Mary C Olmstead; Yves De Koninck; Christopher J Evans; Catherine M Cahill
Journal:  Neuropsychopharmacology       Date:  2015-07-23       Impact factor: 7.853

View more
  20 in total

Review 1.  A Biased View of μ-Opioid Receptors?

Authors:  Alexandra E Conibear; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2019-06-07       Impact factor: 4.436

Review 2.  Alleviating pain with delta opioid receptor agonists: evidence from experimental models.

Authors:  Sophie Berthiaume; Khaled Abdallah; Véronique Blais; Louis Gendron
Journal:  J Neural Transm (Vienna)       Date:  2020-03-18       Impact factor: 3.575

3.  Tolerance to high-internalizing δ opioid receptor agonist is critically mediated by arrestin 2.

Authors:  Ana Vicente-Sanchez; Isaac J Dripps; Alycia F Tipton; Heba Akbari; Areeb Akbari; Emily M Jutkiewicz; Amynah A Pradhan
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

4.  Delta opioid receptor agonists are effective for multiple types of headache disorders.

Authors:  Laura S Moye; Alycia F Tipton; Isaac Dripps; Zoie Sheets; Aimee Crombie; Jonathan D Violin; Amynah A Pradhan
Journal:  Neuropharmacology       Date:  2018-12-14       Impact factor: 5.250

Review 5.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

6.  Opioid-Induced Pronociceptive Signaling in the Gastrointestinal Tract Is Mediated by Delta-Opioid Receptor Signaling.

Authors:  Josue Jaramillo-Polanco; Cintya Lopez-Lopez; Yang Yu; Emma Neary; Alan Hegron; Meritxell Canals; Nigel W Bunnett; David E Reed; Alan E Lomax; Stephen J Vanner
Journal:  J Neurosci       Date:  2022-03-07       Impact factor: 6.709

7.  A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.

Authors:  Zachariah Bertels; Wiktor D Witkowski; Sarah Asif; Kendra Siegersma; Richard M van Rijn; Amynah A Pradhan
Journal:  Headache       Date:  2020-12-16       Impact factor: 5.887

8.  Delta opioid receptor regulation of calcitonin gene-related peptide dynamics in the trigeminal complex.

Authors:  Laura S Moye; Kendra Siegersma; Isaac Dripps; Wiktor Witkowski; Elizaveta Mangutov; Dong Wang; Grégory Scherrer; Amynah A Pradhan
Journal:  Pain       Date:  2021-08-01       Impact factor: 7.926

Review 9.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

10.  β-Arrestin-dependent ERK signaling reduces anxiety-like and conditioned fear-related behaviors in mice.

Authors:  Mee Jung Ko; Terrance Chiang; Arbaaz A Mukadam; Grace E Mulia; Anna M Gutridge; Angel Lin; Julia A Chester; Richard M van Rijn
Journal:  Sci Signal       Date:  2021-08-03       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.